Ani Pharmaceuticals (ANIP) Income from Continuing Operations (2011 - 2026)
Ani Pharmaceuticals (ANIP) posted Income from Continuing Operations of 29492000.0 for Q1 2026, up 7.15% sequentially from 27525000.0 in Q4 2025, and up 88.0% YoY from 15687000.0 in Q1 2025.
Ani Pharmaceuticals (ANIP) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Income from Continuing Operations for 16 years, with the latest figure at 29492000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 88.0% year-over-year to 29492000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 92159000.0 (up 537.39% YoY) and the FY2025 annual result came in at 78337000.0, up 522.94% from the prior year.
- Income from Continuing Operations climbed to 29492000.0 in Q1 2026 per ANIP's latest filing, from 27525000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 29492000.0 in Q1 2026 and troughed at 24198000.0 in Q3 2024.
- A 5-year average of 3541470.59 and a median of 1465000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations sank 23472.09% in 2022, then surged 1144.71% in 2024.
- Over 5 years, Income from Continuing Operations stood at 4280000.0 in 2022, then jumped by 126.96% to 1154000.0 in 2023, then sank by 990.12% to 10272000.0 in 2024, then surged by 367.96% to 27525000.0 in 2025, then climbed by 7.15% to 29492000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 29492000.0, 27525000.0, and 26617000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 24.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.70 Mn |
| Mar 31, 2026 | 29.49 Mn |
| Dec 31, 2025 | 27.53 Mn |
| Sep 30, 2025 | 26.62 Mn |
| Jun 30, 2025 | 8.53 Mn |
| Mar 31, 2025 | 15.69 Mn |
| Dec 31, 2024 | -10.27 Mn |
| Sep 30, 2024 | -24.20 Mn |
| Jun 30, 2024 | -2.29 Mn |
| Mar 31, 2024 | 18.24 Mn |
| Dec 31, 2023 | 1.15 Mn |
| Sep 30, 2023 | 9.91 Mn |
| Jun 30, 2023 | 6.25 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2022 | -4.28 Mn |
| Sep 30, 2022 | -8.60 Mn |
| Jun 30, 2022 | -14.92 Mn |
| Mar 31, 2022 | -20.10 Mn |
| Dec 31, 2021 | -24.14 Mn |
| Sep 30, 2021 | -4.42 Mn |